Chemoprevention is an important strategy for reduction of breast cancer incidence. However, women's adherence to the currently available strategies is very low mostly because of the severe adverse effects. Our group has been focusing on the development and evaluation of nanocarriers containing drug combinations as potential new strategies for pharmacological prevention of breast cancer. In this project, we will assess whether and how (i) nanoencapsulation and (ii) combination of drugs influence the viability and migration of breast cancer (MCF7 and T47D) cells. Additionally, effects on non-tumoral (MCF10) cells will be assessed to verify safety and selectivity. We will focus on combinations of piplartine, fenretinide, 5-fluorouracyl and perillyl alcohol to determine additive and synergistic effects, and these drugs will be incorporated at selected combinations in lipid nanocarriers.
News published in Agência FAPESP Newsletter about the scholarship: